Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal
disorders including metabolic syndrome, cardiovascular disease, and obesity.